抗线粒体抗体对原发性胆汁性肝硬化诊断价值研究进展

doi:10.3969/j.issn.1672-5069.2014.02.030

Abstract

Abstract: Primary biliary cirrhosis is a chronic, slowly progressive cholestatic liver disease of unknown etiology. The antimitochondrial antibody detected in the blood is specific and wih high sensitivity for the diagnosis of PBC. Recent years,with the increased acknowledge of clinic phsicians and the popular of the detection of autoantibodies, the incidence and prevalence has increasing trend year by year,early diagnosis and treatment have great significance on the prognosis of the disease. This researth is focused on the significance of the antimitochondrial antibody and its subtypes in diagnosing of primary biliary cirrhosis.

Key words: Primary biliary cirrhosis, antimitochondrial antibody, Diagnosis

Liu ran review， Lu Lun-gen reviser. Advances of the researth of the value of antimitochondrial antibody in the diagnosis of primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 218-220.

References

[1] Hohenester S，Oude-Elferink RP，Beuers U. Primary biliary cirrhosis. Semin Immunopathol，2009，31:283-307.
[2] Gershwin ME，Mackay IR. The causes of primary biliary cirrhosis convenient and inconvenient truths. Hepatology，2008，47:737-745.
[3] He XS，Ansari AA，Ridqway WM，et al. New insight is to the immunopathology and autoimmune in primary biliary cirrhosis. Cell Immunol，2006，239（1）:12-13.
[4] Rust C，Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol，2008，14:3368-3373.
[5] Pusl T，Beuers U. Extrahepatic manifestations of cholestatic liver diseases:pathogenesis and therapy. Clin Rev Allergy Immunol，2005，28:147-157.
[6] 张玮，王磊，王奕，等. 1039例隐源性肝炎患者AMA-M2抗体的筛查．实用肝脏病杂志，2012，15（3）:238-240．
[7] Beuers U，Boberg KM，Chapman RW，European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of cholestatic liver diseases. J Hepatol，2009，51（2）:237-267.
[8] 陆伦根，田丽艳，徐铭益，等. 欧洲肝病学会临床实践指南: 胆汁淤积性肝病的治疗（2）．肝脏，2009，12（14）：476-478．
[9] Invernizzi P，Selmi C，Gershwin ME. Update on primary biliary cirrhosis. Dig Liver Dis，2010，42:401-408.
[10] Poupon R. Primary biliary cirrhosis:a 2010 update. J Hepatol， 2010，52:745-758.
[11] Tanaka A，Nezu S，Uegaki S，et al. The clinical significance of IgA antimi-tochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann NY Acad Sci，2007，1107:259.
[12] Braun S，Berg C，Buck S，et al. Catalytic domain of PDC-E2 contains epitopes recognized by antimitochondrial antibodies in primary biliary cirrhosis. World J Gastroenterol，2010，16（8）:973.
[13] Berg C P，Stein G M，Klein R， et al. Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M 4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. Liver Int，2006，26:846.
[14] Klein R，Pointner H，Zilly W，et al. Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course:a prospective study on 200 patients followed for 10 years. Liver，1997，17:119.
[15] Feuchtinger M，Christ S，Preuss B，et al. Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. Gut，2009，58:983-989.
[16] Mitchison HC，Bassendine MF，Hendrick A，et al. Positive antimitochondrial antibody but normal alkaline phosphatase:is this primary biliary cirrhosis Hepatology，1986，6:1279-1284.
[17] Metcalf JV，Mitchison HC，Palmer JM，et al. Natural history of early primary biliary cirrhosis. Lancet，1996，348:1399-402.
[18] Springer J，Cauch-Dudek K，O’Rourke K，et al. Asymptomatic primary biliary cirrhosis:a study of its natural history and prognosis. Am J Gastroenterol，1999，94:47-53.
[19] Prince M，Chetwynd A，Newman W，et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years. Gastroenterology，2002，123:1044-1051.
[20] Prince MI，Chetwynd A，Craig WL，et al. Asymptomatic primary biliary cirrhosis:clinical features，prognosis，and symptom progression in a large population based cohort. Gut，2004，53:865-870.
[21] Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology，2000，31:1005-1013.
[22] Van Norstrand MD，Malinchoc M，Lindor KD，et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology，1997，25:6-11.
[23] Heseltine L，Turner IB，Fussey SP，et al. Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology，1990，99:1786-1792.
[24] Muratori L，Muratori P，Granito A，et al. The Western immunoblotting pattern of antimitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Dig Liver Dis，2005，37:108-112.
[25] Masuda J，Omagari K，Ohba K，et al. Correlation between histopathological findings of the liver and IgA class antibodies to 2-oxo-acid dehydrogenase complex in primary biliary cirrhosis. Dig Dis Sci，2003，48:932-938.
[26] Omagari K，Kadokawa Y，Nakamura M，et al. IgA class antibodies to 2-oxo-acid dehydrogenase complex are not predictive markers of histopathological progression in primary biliary cirrhosis. Autoimmunity，2006，39:107-112.
[27] Kisand KE，Kisand KV，Karvonen AL，et al. Antibodies to pyruvate dehydrogenase in primary biliary cirrhosis:correlation with histology. APMIS， 1998，106:884-892.
[28] Rigopoulou E，Davies E，Bogdanos D，et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int，2007，27:1226-1231.
[29] Mattalia A，Luttig B，Rosina F，et al. Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis. J Autoimmun，1997，10:491-497.
[30] Dubel L，Farges O，Courvalin JC，et al. Persistence of gp210 and multiple nuclear dots antibodies does not correlate with recurrence of primary biliary cirrhosis 6 years after liver transplantation. J Hepatol，1998，28:169-170.
[31] Liu B，Shi X H，Zhang FC，et al. Antimitochondrial antibody-negative primary biliary cirrhosis:a subset of primary biliary cirrhosis.Liver Int，2008，28:233-239.
[32] Mendes F，Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis.Gastroenterol Clin North Am，2008，37:479-484.
[33] D hnrich C，Pares A，Caballeria L，et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem，2009，55:978-985.
[34] Oertelt S，Rieger R，Selmi C，et al. A sensitive bead assay for antimitochondrial antibodies:Chipping a way at AMA-negative primary biliary cirrhosis. Hepatology，2007，45:659-665.
[35] Hirschfield GM，Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis.Clin Liver Dis，2008，12:323-331.
[36] Nakamura M，Kondo H，Mori T，et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology，2007，45:118-127.
[37] Granito A，Muratori P，Muratori L，et al. Antinuclear antibodies giving the‘multiple nuclear dots’ or the‘rim-like/membranous’ patterns:diagnostis accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther，2006，24:1575-1583.
[38] Gao L，Tian X，Liu B，et al. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med，2008，8:9-15.

Advances of the researth of the value of antimitochondrial antibody in the diagnosis of primary biliary cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[4]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[5]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[6]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[7]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[8]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[9]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[10]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[11]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[12]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[13]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[14]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[15]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.